Immunic Inc (NASDAQ:IMUX) announced that it will participate in multiple investor and scientific conferences in February.
CEO Daniel Vitt will attend the BIO CEO & Investor Conference and Oppenheimer's Healthcare Life Sciences Conference.
The company will present clinical and preclinical data on IMU-856 at the ECCO Congress in Berlin and discuss vidofludimus calcium (IMU-838) at the Neuroimmunology Drug Development Summit and ACTRIMS Forum.
Presentations and posters will be available on Immunic’s website.